Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis

Next Previous
Trial Profile

A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rozibafusp alfa (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Amgen

Most Recent Events

  • 17 Mar 2021 Results of pharmacokinetic and PK/PD from phase I studies in healthy and RA subjects (NCT02618967, NCT03156023) presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 03 Jul 2020 Status changed from active, no longer recruiting to completed.
  • 06 Jun 2020 Interim results (As of June 5, 2019; n= 34) presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top